User login
CHICAGO –
The usual tool for trying to detect recurrence while following patients with papillary thyroid cancer after surgery has been the serum thyroglobulin assay. However, management of papillary thyroid cancer has become more conservative, involving lobectomy and isthmusectomy on the affected side rather than total gland resection. The benefit of the conservative approach is to avoid complications while maintaining an overall survival rate equivalent to the more extensive approach.
The investigators measured 754 miRNAs in serum samples of 11 patients with papillary thyroid cancer both before and 30 days after surgical thyroidectomy. They re-evaluated major candidate miRNAs using absolute quantitative polymerase chain reaction analysis in an independent cohort of 44 other patients with papillary thyroid cancer or benign nodules or 20 healthy controls, Dr. Rosignolo said at the annual meeting of the Endocrine Society.
The 2 miRNAs most significantly associated with thyroid tumors were then assessed in matched serum samples (before and 30 days, and 1 to 2 years after surgery) from the 20 PTC patients with complete follow-up datasets and results correlated with American Thyroid Association (ATA) responses to therapy.
Serum levels of both miRNAs after 1 to 2 years of follow-up were consistent with ATA responses to therapy in all patients, including two patients who developed structural evidence of disease whose thyroglobulin assay results remained negative (less than 1 ng/mL) for cancer recurrence.
Fifteen of the 20 patients had excellent or indeterminate responses to therapy as defined by 2015 ATA guidelines. In these 15 cases, and in the single patient with a biochemical incomplete response, expression levels of miR-146a-5p and miR-221-3p decreased after surgery and remained low at the 1- to 2-year visit.
It was a very different story for the 4 patients with structural incomplete responses at 1 to 2 years. In this subgroup, initial postoperative declines in serum miR-146a-5p and miR-221-3p levels were followed by increases to levels at the 1- to 2-year visit that were similar to or higher than those found prior to surgery.
The study was funded by the Umberto Di Mario Foundation, Banca d’Italia, University of Rome Sapienza, the program of Biotechnologies and Clinical Medicine of the University of Rome Sapienza, the European Medical Writers Association, and the Umberto Di Mario Foundation.
SOURCE: Rosignolo F et al. J Endo Soc. 2017;1(1)3-13. ENDO 2018, Abstract OR17-1.
CHICAGO –
The usual tool for trying to detect recurrence while following patients with papillary thyroid cancer after surgery has been the serum thyroglobulin assay. However, management of papillary thyroid cancer has become more conservative, involving lobectomy and isthmusectomy on the affected side rather than total gland resection. The benefit of the conservative approach is to avoid complications while maintaining an overall survival rate equivalent to the more extensive approach.
The investigators measured 754 miRNAs in serum samples of 11 patients with papillary thyroid cancer both before and 30 days after surgical thyroidectomy. They re-evaluated major candidate miRNAs using absolute quantitative polymerase chain reaction analysis in an independent cohort of 44 other patients with papillary thyroid cancer or benign nodules or 20 healthy controls, Dr. Rosignolo said at the annual meeting of the Endocrine Society.
The 2 miRNAs most significantly associated with thyroid tumors were then assessed in matched serum samples (before and 30 days, and 1 to 2 years after surgery) from the 20 PTC patients with complete follow-up datasets and results correlated with American Thyroid Association (ATA) responses to therapy.
Serum levels of both miRNAs after 1 to 2 years of follow-up were consistent with ATA responses to therapy in all patients, including two patients who developed structural evidence of disease whose thyroglobulin assay results remained negative (less than 1 ng/mL) for cancer recurrence.
Fifteen of the 20 patients had excellent or indeterminate responses to therapy as defined by 2015 ATA guidelines. In these 15 cases, and in the single patient with a biochemical incomplete response, expression levels of miR-146a-5p and miR-221-3p decreased after surgery and remained low at the 1- to 2-year visit.
It was a very different story for the 4 patients with structural incomplete responses at 1 to 2 years. In this subgroup, initial postoperative declines in serum miR-146a-5p and miR-221-3p levels were followed by increases to levels at the 1- to 2-year visit that were similar to or higher than those found prior to surgery.
The study was funded by the Umberto Di Mario Foundation, Banca d’Italia, University of Rome Sapienza, the program of Biotechnologies and Clinical Medicine of the University of Rome Sapienza, the European Medical Writers Association, and the Umberto Di Mario Foundation.
SOURCE: Rosignolo F et al. J Endo Soc. 2017;1(1)3-13. ENDO 2018, Abstract OR17-1.
CHICAGO –
The usual tool for trying to detect recurrence while following patients with papillary thyroid cancer after surgery has been the serum thyroglobulin assay. However, management of papillary thyroid cancer has become more conservative, involving lobectomy and isthmusectomy on the affected side rather than total gland resection. The benefit of the conservative approach is to avoid complications while maintaining an overall survival rate equivalent to the more extensive approach.
The investigators measured 754 miRNAs in serum samples of 11 patients with papillary thyroid cancer both before and 30 days after surgical thyroidectomy. They re-evaluated major candidate miRNAs using absolute quantitative polymerase chain reaction analysis in an independent cohort of 44 other patients with papillary thyroid cancer or benign nodules or 20 healthy controls, Dr. Rosignolo said at the annual meeting of the Endocrine Society.
The 2 miRNAs most significantly associated with thyroid tumors were then assessed in matched serum samples (before and 30 days, and 1 to 2 years after surgery) from the 20 PTC patients with complete follow-up datasets and results correlated with American Thyroid Association (ATA) responses to therapy.
Serum levels of both miRNAs after 1 to 2 years of follow-up were consistent with ATA responses to therapy in all patients, including two patients who developed structural evidence of disease whose thyroglobulin assay results remained negative (less than 1 ng/mL) for cancer recurrence.
Fifteen of the 20 patients had excellent or indeterminate responses to therapy as defined by 2015 ATA guidelines. In these 15 cases, and in the single patient with a biochemical incomplete response, expression levels of miR-146a-5p and miR-221-3p decreased after surgery and remained low at the 1- to 2-year visit.
It was a very different story for the 4 patients with structural incomplete responses at 1 to 2 years. In this subgroup, initial postoperative declines in serum miR-146a-5p and miR-221-3p levels were followed by increases to levels at the 1- to 2-year visit that were similar to or higher than those found prior to surgery.
The study was funded by the Umberto Di Mario Foundation, Banca d’Italia, University of Rome Sapienza, the program of Biotechnologies and Clinical Medicine of the University of Rome Sapienza, the European Medical Writers Association, and the Umberto Di Mario Foundation.
SOURCE: Rosignolo F et al. J Endo Soc. 2017;1(1)3-13. ENDO 2018, Abstract OR17-1.
REPORTING FROM ENDO 2018
Key clinical point: Serum microRNA profiles hold promise for postsurgical monitoring of patients with papillary thyroid cancer.
Major finding: Of eight tested, two serum microRNA profiles – miR-146a-5p and miR-221-3p – were the most promising thyroid tumor biomarkers.
Study details: Prospective analysis of the blood of 31 patients with papillary thyroid cancer before and after surgery to assess which markers were most sensitive to cancer.
Disclosures: The study was funded by the Umberto Di Mario Foundation, Banca d’Italia, University of Rome Sapienza, the program of Biotechnologies and Clinical Medicine of the University of Rome Sapienza, the European Medical Writers Association, and the Umberto Di Mario Foundation.
Source: Rosignolo F et al. J Endo Soc. 2017;1(1):3-13. ENDO 2018, Abstract OR17-1.